Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308235 | 1.00 | KLK5 (0.47) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6308157 | 0.93 | KLK5 (0.47) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6304827 | 0.93 | KLK5 (0.47) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6311500 | 0.92 | KLK5 (0.50) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6312323 | 0.92 | KLK5 (0.50) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6312890 | 0.92 | KLK5 (0.47) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6670426 | 0.91 | KLK5 (0.48) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6307411 | 0.91 | KLK5 (0.48) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6309151 | 0.91 | KLK5 (0.48) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6397063 | 0.91 | KLK5 (0.48) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS | 2005-07-21 | — | — | US | claimed |
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS | 2005-07-21 | — | — | US | disclosed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005026-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | BACE1, APP, BACE2 | KLK5 1643/4885PSEN1 5/4885PSEN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.